<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02657148</url>
  </required_header>
  <id_info>
    <org_study_id>PRO15070357</org_study_id>
    <secondary_id>IIS#53505</secondary_id>
    <nct_id>NCT02657148</nct_id>
  </id_info>
  <brief_title>Immediate Postpartum Nexplanon Placement in Opioid Dependent Women</brief_title>
  <official_title>A Prospective Observational Clinical Trial to Compare the Effect of Immediate Postpartum Nexplanon Placement Versus Standard Postpartum Contraceptive Care on Consistent Contraceptive Use and Rapid Repeat Pregnancy in Opioid Dependent Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators have designed a single site, Phase IV open label, prospective observational
      clinical trial to compare the effect of immediate postpartum Nexplanon placement (IPP) versus
      standard postpartum contraceptive care (control) on consistent contraceptive use and rapid
      repeat pregnancy at 12 months postpartum in 200 opioid dependent (OD) women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Opioid dependence in pregnancy has increased dramatically in the last decade.
      Over 86% of pregnancies conceived by OD women are unintended, compared to 31-43% of
      pregnancies in the general population. In evaluations of contraceptive use among sexually
      active women in opioid treatment programs, 40-75% of sexually active OD women report no
      contraceptive use. Even among women using contraception, 45-55% report using only condoms
      without more effective, hormonal contraception. Pregnancy and the postpartum period are
      unique opportunities to provide contraceptive education and services. Long-acting reversible
      contraception (LARC) has been shown to more effectively prevent rapid repeat, unintended
      pregnancies compared to other postpartum contraceptive options and does not incur the risk of
      venous thromboembolism associated with estrogen-containing methods (i.e. pills, ring, patch).
      No studies have evaluated the impact of immediate postpartum etonogestrel implant (Nexplanon)
      placement on reproductive health outcomes in OD women, a population at significant risk for
      rapid repeat, unintended pregnancy. In contrast to an intrauterine device (IUD), Nexplanon is
      safe to insert regardless of labor and delivery circumstances, does not incur an increased
      risk of postpartum expulsion and is long-acting, which makes it the ideal contraceptive for
      the immediate postpartum period.

      Study site:This single site study will be conducted at Magee-Womens Hospital (MWH) of the
      University of Pittsburgh Medical Center.

      Study Procedures: Recruitment - participants will be recruited during the third trimester of
      pregnancy (≥ 28 weeks gestation) during prenatal care visits.

      Immediate postpartum Nexplanon placement (IPP) - participants who choose to enroll in the IPP
      Nexplanon arm will have Nexplanon placed in the immediate postpartum period (2-4 days
      following delivery), prior to hospital discharge.

      Standard postpartum contraceptive care (control) - participants who choose to enroll in the
      control arm will receive a contraceptive method of their choice according to standard
      clinical protocols. Standard clinical protocols include condoms, Depo Provera (DMPA) or
      progestin-only pills initiated at any time after delivery, Nexplanon insertion at &gt; 4 weeks
      after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any
      time &gt; 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion
      any time &gt; 6 weeks after delivery.

      Study Duration: 12 months
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Consistent contraception</measure>
    <time_frame>12 months postpartum</time_frame>
    <description>Number of participants who use highly effective contraception (all hormonal methods or the copper T380 IUD) for ≥ 80% of the first postpartum year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rapid, repeat pregnancy</measure>
    <time_frame>12 months postpartum</time_frame>
    <description>Number of participants who have a repeat pregnancy within 12 months after delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breastfeeding initiation</measure>
    <time_frame>12 months postpartum</time_frame>
    <description>Number of participants who breastfeed after delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum depression</measure>
    <time_frame>12 months postpartum</time_frame>
    <description>Edinburgh Postnatal Depression Scale scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant weight gain</measure>
    <time_frame>12 months</time_frame>
    <description>Infant weight in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant development</measure>
    <time_frame>12 months</time_frame>
    <description>Number of infants that achieve developmental milestones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-risk sexual behavior</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants who use condoms</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Opiate Addiction</condition>
  <condition>Pregnancy</condition>
  <condition>Contraceptive Behavior</condition>
  <condition>Sexual Behavior</condition>
  <arm_group>
    <arm_group_label>Immediate postpartum Nexplanon</arm_group_label>
    <description>Participants who choose to enroll in the immediate postpartum Nexplanon arm will have a etonogestrel contraceptive implant (68 mg) (Nexplanon) placed in the immediate postpartum period (2-4 days following delivery), prior to hospital discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Participants who choose to enroll in the control arm will receive standard postpartum contraceptive care: condoms, Depo Provera (DMPA) or progestin-only pills initiated at any time after delivery, Nexplanon insertion at &gt; 4 weeks after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any time &gt; 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion any time &gt; 6 weeks after delivery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nexplanon (etonogestrel contraceptive implant)</intervention_name>
    <description>Nexplanon is a single, radiopaque, rod-shaped implant, containing 68 mg etonogestrel indicated for postpartum contraceptive use by women to prevent pregnancy. Nexplanon is designed to be effective for 3 years.</description>
    <arm_group_label>Immediate postpartum Nexplanon</arm_group_label>
    <other_name>Nexplanon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard postpartum contraceptive care</intervention_name>
    <description>Condoms, Depo Provera (DMPA) or progestin-only pills initiated at any time after delivery, Nexplanon insertion at &gt; 4 weeks after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any time &gt; 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion any time &gt; 6 weeks after delivery.</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Postpartum contraception</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women, 18 years or older, who meet DSM-V criteria for opioid use disorder
        confirmed by diagnostic coding in the patient's medical record and/or urinary toxicology
        screen (UDS) and who plan to deliver at the study site hospital, Magee-Womens Hospital of
        UPMC (MWH-UPMC).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: Pregnant women, 18 years or older, who meet DSM-V criteria for opioid
        use disorder confirmed by diagnostic coding in the patient's medical record and/or urinary
        toxicology screen (UDS) and who plan to deliver at the study site hospital, Magee-Womens
        Hospital of UPMC (MWH-UPMC).

        Exclusion Criteria: Women who have contraindications to etonogestrel use, intrauterine
        fetal demise or stillbirth, and/or who do not plan to deliver at MWH-UPMC.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth E Krans, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Magee-Womens Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA. 2012 May 9;307(18):1934-40. doi: 10.1001/jama.2012.3951. Epub 2012 Apr 30.</citation>
    <PMID>22546608</PMID>
  </reference>
  <reference>
    <citation>Heil SH, Jones HE, Arria A, Kaltenbach K, Coyle M, Fischer G, Stine S, Selby P, Martin PR. Unintended pregnancy in opioid-abusing women. J Subst Abuse Treat. 2011 Mar;40(2):199-202. doi: 10.1016/j.jsat.2010.08.011. Epub 2010 Oct 30.</citation>
    <PMID>21036512</PMID>
  </reference>
  <reference>
    <citation>Rabin RF, Jennings JM, Campbell JC, Bair-Merritt MH. Intimate partner violence screening tools: a systematic review. Am J Prev Med. 2009 May;36(5):439-445.e4. doi: 10.1016/j.amepre.2009.01.024. Review.</citation>
    <PMID>19362697</PMID>
  </reference>
  <reference>
    <citation>van Bussel JC, Spitz B, Demyttenaere K. Reliability and validity of the Dutch version of the maternal antenatal attachment scale. Arch Womens Ment Health. 2010 Jun;13(3):267-77. doi: 10.1007/s00737-009-0127-9. Epub 2009 Oct 27. Erratum in: Arch Womens Ment Health. 2010 Jun;13(3):293-4.</citation>
    <PMID>19859787</PMID>
  </reference>
  <reference>
    <citation>Brito MB, Ferriani RA, Quintana SM, Yazlle ME, Silva de Sá MF, Vieira CS. Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study. Contraception. 2009 Dec;80(6):519-26. doi: 10.1016/j.contraception.2009.05.124. Epub 2009 Jul 10.</citation>
    <PMID>19913145</PMID>
  </reference>
  <reference>
    <citation>Tocce K, Sheeder J, Python J, Teal SB. Long acting reversible contraception in postpartum adolescents: early initiation of etonogestrel implant is superior to IUDs in the outpatient setting. J Pediatr Adolesc Gynecol. 2012 Feb;25(1):59-63. doi: 10.1016/j.jpag.2011.09.003. Epub 2011 Nov 3.</citation>
    <PMID>22051792</PMID>
  </reference>
  <reference>
    <citation>Grimes DA, Lopez LM, Schulz KF, Van Vliet HA, Stanwood NL. Immediate post-partum insertion of intrauterine devices. Cochrane Database Syst Rev. 2010 May 12;(5):CD003036. doi: 10.1002/14651858.CD003036.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;6:CD003036.</citation>
    <PMID>20464722</PMID>
  </reference>
  <reference>
    <citation>Tocce KM, Sheeder JL, Teal SB. Rapid repeat pregnancy in adolescents: do immediate postpartum contraceptive implants make a difference? Am J Obstet Gynecol. 2012 Jun;206(6):481.e1-7. doi: 10.1016/j.ajog.2012.04.015. Epub 2012 Apr 16.</citation>
    <PMID>22631865</PMID>
  </reference>
  <reference>
    <citation>Sinha C, Guthrie KA, Lindow SW. A survey of postnatal contraception in opiate-using women. J Fam Plann Reprod Health Care. 2007 Jan;33(1):31-4.</citation>
    <PMID>17389093</PMID>
  </reference>
  <reference>
    <citation>Gipson JD, Koenig MA, Hindin MJ. The effects of unintended pregnancy on infant, child, and parental health: a review of the literature. Stud Fam Plann. 2008 Mar;39(1):18-38. Review.</citation>
    <PMID>18540521</PMID>
  </reference>
  <reference>
    <citation>Baldwin MK, Edelman AB. The effect of long-acting reversible contraception on rapid repeat pregnancy in adolescents: a review. J Adolesc Health. 2013 Apr;52(4 Suppl):S47-53. doi: 10.1016/j.jadohealth.2012.10.278. Review.</citation>
    <PMID>23535057</PMID>
  </reference>
  <reference>
    <citation>Morrison CL, Ruben SM, Beeching NJ. Female sexual health problems in a drug dependency unit. Int J STD AIDS. 1995 May-Jun;6(3):201-3.</citation>
    <PMID>7647124</PMID>
  </reference>
  <reference>
    <citation>Armstrong KA, Kenen R, Samost L. Barriers to family planning services among patients in drug treatment programs. Fam Plann Perspect. 1991 Nov-Dec;23(6):264-6, 270-1.</citation>
    <PMID>1786807</PMID>
  </reference>
  <reference>
    <citation>Ralph N, Spigner C. Contraceptive practices among female heroin addicts. Am J Public Health. 1986 Aug;76(8):1016-7.</citation>
    <PMID>3728758</PMID>
  </reference>
  <reference>
    <citation>Armstrong KA, Kennedy MG, Kline A, Tunstall C. Reproductive health needs: comparing women at high, drug-related risk of HIV with a national sample. J Am Med Womens Assoc (1972). 1999 Spring;54(2):65-70, 78.</citation>
    <PMID>10319594</PMID>
  </reference>
  <reference>
    <citation>Black KI, Stephens C, Haber PS, Lintzeris N. Unplanned pregnancy and contraceptive use in women attending drug treatment services. Aust N Z J Obstet Gynaecol. 2012 Apr;52(2):146-50. doi: 10.1111/j.1479-828X.2012.01413.x. Epub 2012 Feb 15.</citation>
    <PMID>22335489</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2015</study_first_submitted>
  <study_first_submitted_qc>January 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2016</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Elizabeth Krans, MD</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Obstetrics, Gynecology &amp; Reproductive Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Etonogestrel</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

